| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Dean Slagel last filed a Form 4 in June 2017, as Director at TVRD. Dean Slagel's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,064,338 shares of TVRD. The TVRD filings lean toward selling, a net 482,811 shares.
Dean Slagel has 6 Form 4 filings on record from May 2015 to June 2017, all as Director at Tvardi Therapeutics (TVRD), 2015–2017.
The 10 reported transactions were 7 open-market sales and 3 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $9.1M.
The largest open-market sale was 250,000 shares of TVRD at an average $25.87 on June 29, 2017, about $6.5M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.